These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19638491)

  • 1. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system.
    Kadara H; Lacroix L; Behrens C; Solis L; Gu X; Lee JJ; Tahara E; Lotan D; Hong WK; Wistuba II; Lotan R
    Cancer Prev Res (Phila); 2009 Aug; 2(8):702-11. PubMed ID: 19638491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
    Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
    Wan YW; Beer DG; Guo NL
    Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.
    Sakashita H; Inoue H; Akamine S; Ishida T; Inase N; Shirao K; Mori M; Mimori K
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S590-8. PubMed ID: 23812770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis.
    Feng G; Xu X; Youssef EM; Lotan R
    Cancer Res; 2001 Nov; 61(21):7999-8004. PubMed ID: 11691825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 7. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer.
    Chong IW; Chang MY; Chang HC; Yu YP; Sheu CC; Tsai JR; Hung JY; Chou SH; Tsai MS; Hwang JJ; Lin SR
    Oncol Rep; 2006 Nov; 16(5):981-8. PubMed ID: 17016581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
    Lu Y; Wang L; Liu P; Yang P; You M
    PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
    Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
    Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
    Liu X; Liu X; Li J; Ren F
    Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer.
    Guo NL; Wan YW; Tosun K; Lin H; Msiska Z; Flynn DC; Remick SC; Vallyathan V; Dowlati A; Shi X; Castranova V; Beer DG; Qian Y
    Clin Cancer Res; 2008 Dec; 14(24):8213-20. PubMed ID: 19088038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.
    Truesdell P; Ahn J; Chander H; Meens J; Watt K; Yang X; Craig AW
    Oncogene; 2015 Jul; 34(27):3527-35. PubMed ID: 25174397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANTES expression is a predictor of survival in stage I lung adenocarcinoma.
    Moran CJ; Arenberg DA; Huang CC; Giordano TJ; Thomas DG; Misek DE; Chen G; Iannettoni MD; Orringer MB; Hanash S; Beer DG
    Clin Cancer Res; 2002 Dec; 8(12):3803-12. PubMed ID: 12473593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
    Xie Y; Xiao G; Coombes KR; Behrens C; Solis LM; Raso G; Girard L; Erickson HS; Roth J; Heymach JV; Moran C; Danenberg K; Minna JD; Wistuba II
    Clin Cancer Res; 2011 Sep; 17(17):5705-14. PubMed ID: 21742808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array.
    Hofmann HS; Bartling B; Simm A; Murray R; Aziz N; Hansen G; Silber RE; Burdach S
    Oncol Rep; 2006 Sep; 16(3):587-95. PubMed ID: 16865260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.
    Feng A; Tu Z; Yin B
    Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A innovative prognostic symbol based on neutrophil extracellular traps (NETs)-related lncRNA signature in non-small-cell lung cancer.
    Fang C; Liu F; Wang Y; Yuan S; Chen R; Qiu X; Qian X; Zhang X; Xiao Z; Wang Q; Fu B; Li Y
    Aging (Albany NY); 2021 Jul; 13(13):17864-17879. PubMed ID: 34257164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.
    Selvaraj G; Kaliamurthi S; Kaushik AC; Khan A; Wei YK; Cho WC; Gu K; Wei DQ
    J Biomed Inform; 2018 Oct; 86():120-134. PubMed ID: 30195659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
    Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.